大公司动态丨风向变了？马斯克提醒狗狗币风险；中信称禁止使用账户用于比特币交易

中国人寿保险股份有限公司重庆市分公司发布声明称，近日，公司永川支公司在对一位意外身故客户的家属作出大额赔付的过程中，相关工作人员出现不当宣传行为，造成恶劣影响，对此公司向客户家属和广大民众表示深深的歉意。公司已诚恳向客户家属当面致歉并取得谅解，同时对支公司经理进行免职处理，并对其他相关人员开展批评教育。（中证网）

In a statement issued by Chongqing City Branch, China Life Insurance Company, Inc., it stated that in recent days, in the course of paying a large sum to the family of an unexpected client, the company's staff members had been misadventured, with adverse effects, and expressed their deep apologies to the client's family and the public at large. The company had sincerely apologized to the client's family and obtained an understanding, and had dismissed the manager of the subsidiary and had conducted critical education for other concerned personnel.

【医药】

{\bord0\shad0\alphaH3D}Pharma.

药明生物宣布完成三笔收购，包括辉瑞中国生物药原液和制剂生产基地

Three acquisitions were announced by , including Pfizer China's biopharmaceutical liquid and agent production base

药明生物宣布已完成对拜耳位于德国伍珀塔尔的原液生产基地，辉瑞中国位于杭州的原液和制剂生产基地以及中国生物药合同研发生产企业（CDMO）苏桥生物的三笔收购。以上收购的原液和制剂生产基地将于今年内陆续启动GMP生产。预计到2021年底，药明生物将在中国、美国和德国共运营11个原液厂，原液总产能将升至15万升。（财联社）

Pharmacy organisms have announced the completion of three acquisitions of raw liquid production sites in Bayer in Woopertar, Germany, and Pfizer China's primary liquid and agent production base in Hangzhou, as well as the Chinese biopharmaceuticals contract for the development and production of Subridge organisms. The primary liquid and agent production sites purchased above will start GMP production inland this year. It is expected that by the end of 2021 there will be a total of 11 former liquid plants operating in China, the United States and Germany, and that the original total liquid production capacity will rise to 150,000 litres.

【疫苗】

{\bord0\shad0\alphaH3D}According to the {\bord0\shad0\alphaH3D}According to the {\bord0\shad0\alphaH3D}According to the {\bord0\shad0\alphaH3D}According to the {\bord0\shad0\alphaH3D}According to the {\bord0\shad0\alphaH3D}

辉瑞和BioNTech提高今年疫苗产能目标

Pfizer and BioNTech to improve this year's vaccine production targets

BioNTech SE和辉瑞公司上调产量目标，今年新冠疫苗产能将达到30亿剂。为了提高全球疫苗产量，药企面临豁免专利保护的压力。BioNTech在声明中表示，专利不是影响我们疫苗生产或供应的限制因素。豁免专利不会在短期和中期增加生产和供应。建立和验证新的疫苗生产基地通常需要长达一年的时间。（新浪财经）

BioNTech SE and Pfizer will raise production targets to 3 billion doses this year. In order to increase global vaccine production, pharmaceutical companies are under pressure to exempt from patent protection. BioNTech stated in his statement that patents are not a constraint on our vaccine production or supply. Exemptions do not increase production and supply in the short and medium term.

【食品】

{\bord0\shad0\alphaH3D}Strange. {\bord0\shad0\alphaH3D}